Search results
Stelara subcutaneous: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD
WebMD· 2 days agoBruising, itching, pain, redness, swelling, or hardening of the skin at the injection site may occur. Injection site reactions usually go away after 1 or 2 days. Remember that this medication ...
It’s time we stop corporate pharmaceutical companies from using their power to rig the rules - The...
The Boston Globe· 5 hours agoMost Rhode Islanders agree that everyone, no matter where they come from or how much money they...
My patients can’t afford two crucial medications, and Big Pharma should be held accountable
Colorado Newsline via Yahoo News· 4 days agoAs a physician, I am encouraged and impressed with the work that Colorado’s Prescription Drug...
State Drug Pricing Boards Forge Ahead With Eyes on Amgen Suit
Bloomberg Law· 6 hours agoState affordability boards seeking to limit what health plans pay for prescription drugs are confident they will withstand legal challenges as Colorado battles what’s expected to be the first ...
AbbVie's tight grip on Humira market raises concerns about biosimilars
Reuters· 3 days ago, opens new tab top-selling arthritis drug Humira has held onto more than 80% of patients after...
The 3 Best Dow Stocks to Buy in June 2024
InvestorPlace· 3 days agoAs we enter June 2024, the Dow Jones Industrial Average continues to be a closely watched barometer of the U.S. stock market. In this article, we will...
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
Zacks via Yahoo Finance· 6 days agoA biosimilar version of AbbVie’s blockbuster immunology medicine, Humira, called Simlandi, was...
DePuy Synthes gets FDA nod for knee surgery robot By Investing.com
Investing.com· 3 days agoJohnson & Johnson's DePuy Synthes has obtained FDA 510(k) clearance for its VELYS™ Robotic-Assisted...
The Dividend Darlings: 3 Stocks That Will Shower Your Portfolio with Cash
InvestorPlace· 3 days agoFrom 1930 to 2023, 70% of dividend stocks in the top two quintiles outperformed the S&P 500 during...
AbbVie's Arthritis Drug Humira Retains Market Dominance Despite Biosimilar Competition, Challenges...
Benzinga· 3 days agoAbbVie Inc’s ABBV top-selling arthritis drug, Humira, has managed to retain over 80% of its patients even after facing nine lower-priced rivals in the U.S. over the past year, Reuters reports ...